3rd Annual MarketsandMarkets

Next-Gen Immuno-Oncology Congress - Virtual Event (Time Zone - ET)

June 25-26, 2020

45+

Speakers

200+

Attendees

4+

Networking Hours

5+

Sessions

Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.

See the Post Show report of our 2nd Annual here

Please write to [email protected] for questions regarding speaking, attending and sponsoring. We will keep you posted with the event flow soon. Keep checking our website.

WHAT TO EXPECT

  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Monoclonal Antibody & Cellular Therapy
  • Neoantigens in personalized Cancer Immunotherapy
  • Biomarkers and Cancer Vaccines
  • Developments in CAR-T Cellular Therapy
  • Oncolytic Viral Therapy & Personalized Medicine
  • Engineering Cellular Therapies Beyond Traditional Tumor Antigens
  • Combination Therapies in I/O

  • Exclusive Virtual event to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive Q&A sessions with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology

CONFERENCE AGENDA

Monoclonal Antibody & Cellular Therapy

Registration

10:40 - 10:50

Opening remark by Chairperson

10:50 - 11:00

Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cell

Geert Mudde

Geert Mudde, CSO and Managing Director, Founder, OncoQR ML GmbH, S-TARget therapeutics

11:00 - 11:25

Panel Discussion: The promises of CAR-T cell therapy in 2020 and beyond

11:25 - 12:00

Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC

Hani Gabra

Hani Gabra , Co-Founder/ Chief Scientific Officer, Papyrus Therapeutics

12:00 - 12:30

Mechanisms of Resistance and Response to anti-CD19 CAR T cell Therapy in LC

John Rossi

John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

12:30 - 12:55

Targeting Bispecific Antibodies and Developing Systems Disease Models in I/O

John M. Burke

John M. Burke, President, CEO, and Co-founder  , Applied BioMath

12:55 - 13:25

REGN4018, a Mucin 16 bispecific T cell engaging antibody for the treatment of ovarian cancer

Alison Crawford

Alison Crawford, Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

13:25 - 13:50

Antibodies & CAR-T Cellular Therapy

Laboratory Considerations for Immuno-Oncology Clinical Trials - Q2 Solutions

13:50 - 14:05

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Eric Halioua

Eric Halioua, President & CEO, PDC*line Pharma

14:05 - 14:30

Deciphering the function of B cells in human cancer

Tullia Bruno

Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh

14:30 - 14:55

Closing remark by chairman

14:55 - 15:00

Networking│One-to-One Networking Meetings

15:00 - 15:30

End of Day 1

15:30 - 15:30

Advancing Precision Medicine: Emerging Therapeutic and Technological Approaches

Registration

10:40 - 10:50

Opening remark by Chairperson

10:50 - 11:00

Are there still unmet needs in ICI therapy?

Stefan Glueck

Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron

11:00 - 11:25

Cannabinoids as companion treatments for cancer

Philip Arlen

Philip Arlen, Chief Scientific Officer, Senior Vice President, Diverse Biotech

11:25 - 11:50

Solution Provider Presentation - Biocytogen

11:50 - 12:20

Solution Provider Presentation - Proteome Sciences

12:20 - 12:50

FDA Accelerated Approval Pathways for Cell and Gene Therapy 

12:50 - 13:20

A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer 

Indu Venugopal

Indu Venugopal , Research Scientist, SRI International

13:20 - 13:45

Cancer Vaccines & Biomarkers

Solution Provider Presentation - PromoCell GmbH

13:45 - 14:15

First-in-class biotherapeutics, designed to “heat up” cold tumor microenvironment for combination therapy with PD(L)1 inhibitors

Christie Zhang

Christie Zhang , Project Team Leader, Elstar Therapeutics

14:15 - 14:40

Oncolytic Viruses: NOTCHing up the game

Balveen Kaur

Balveen Kaur, Professor, The University of Texas Health Science Center

14:40 - 15:05

Closing remark by chairman

15:05 - 15:10

Networking│One-to-One Networking Meetings

15:10 - 15:40

End of Day 1

15:40 - 15:40

Therapeutics antibodies & TCR-based Cellular Therapy

Registrations

10:40 - 10:55

Opening remark by Chairperson

10:55 - 11:00

PD-1 Antibodies are Transforming Cancer Care

11:00 - 11:25

Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates Gamma-Delta (Vg9-Vd2) T Cells

Alem Truneh

Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

11:25 - 11:50

Novel serum-free and xeno-free T cell medium for improved T cell therapy manufacturing

11:50 - 12:20

Solution Provider Presentation - PhenoSwitch Bioscience Inc.

12:20 - 12:50

Completing the immune cycle by targeting novel macrophage checkpoints

Tatiana Novobrantseva

Tatiana Novobrantseva, Co-founder and Chief Scientific Officer, Verseau Therapeutics

12:50 - 13:15

Solution Provider Presentation - PHC Corporation

13:15 - 13:45

Unleashing the Power of SQZ’d Cells to Engineer a New Generation of Cancer Vaccines

Katherine Seidl

Katherine Seidl, Vice President Immunology Research and Development, SQZ Biotechnologies

13:45 - 14:10

Closing remarks from Chairman

14:10 - 14:15

Networking│One-to-One Networking Meetings

14:15 - 14:45

End of Conference

15:00 - 15:00

Registrations

10:40 - 10:55

Opening remark by Chairperson

10:55 - 11:00

Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy 

Nuzhat Pathan

Nuzhat Pathan, Director, Early Development, Translational and Immuno-Oncology, Pfizer

11:00 - 11:25

Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf Approach

William Williams

William Williams, President, CEO, Briacell Therapeutics Corporation

11:25 - 11:50

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

Bradlee Heckmann

Bradlee Heckmann, CSO, Asha Therapeutics

11:50 - 12:20

Unleashing the power of NGS to unlock the secrets of immuno-oncology 

Raed Samara Ph.D

Raed Samara Ph.D , Associate Director, Global Product Management, NGS , QIAGEN

12:20 - 12:50

Preventing drug resistance to targeted therapeutics in ER+HER2- Breast Cancer

Nathaniel Wang

Nathaniel Wang, Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

12:50 - 13:15

Preclinical modeling of immune responses to Cancer: improving translatability of bench-side discoveries to clinical outcomes

Mithun Khattar

Mithun Khattar, Immuno-Oncology Lead, Takeda Oncology

13:15 - 13:40

It’s time to look beyond Checkpoint Blockade

Shailesh Dudhgaonkar

Shailesh Dudhgaonkar , Deputy Research Director , Biocon Bristol Myers Squibb R&D Center (BBRC)

13:40 - 14:05

Closing remarks from Chairman

14:05 - 14:10

Networking│One-to-One Networking Meetings

14:10 - 15:00

End of Conference

15:00 - 15:00

SPEAKERS

Shailendra Singh (Shelly)

Shailendra Singh (Shelly)

Board Member, MarketsandMarkets

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

Mithun Khattar

Mithun Khattar

Immuno-Oncology Lead, Takeda Oncology

Stefan Glueck

Stefan Glueck

Ex- Vice President, Global Head Franchise Oncology, Regeneron

Nuzhat Pathan

Nuzhat Pathan

Director, Early Development, Translational and Immuno-Oncology, Pfizer

Philip Arlen

Philip Arlen

Chief Scientific Officer, Senior Vice President, Diverse Biotech

Nathaniel Wang

Nathaniel Wang

Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

Shailesh Maingi

Shailesh Maingi

Founder and CEO, Kineticos Life Sciences

Soldano Ferrone

Soldano Ferrone

Professor, Harvard University, USA

Christie Zhang

Christie Zhang

Project Team Leader, Elstar Therapeutics

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Alison Crawford

Alison Crawford

Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

William Williams

William Williams

President, CEO, Briacell Therapeutics Corporation

Balveen Kaur

Balveen Kaur

Professor, The University of Texas Health Science Center

Tatiana Novobrantseva

Tatiana Novobrantseva

Co-founder and Chief Scientific Officer, Verseau Therapeutics

Scott Durum

Scott Durum

Head, Cytokines and Immunity, NIH

Patrick Hurban, PhD

Patrick Hurban, PhD

Senior Director and Global Head, Translational Genomics, Q2 Solutions

Indu Venugopal

Indu Venugopal

Research Scientist, SRI International

Lokesh Agrawal

Lokesh Agrawal

Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH

Katherine Seidl

Katherine Seidl

Vice President Immunology Research and Development, SQZ Biotechnologies

Tullia Bruno

Tullia Bruno

Assistant Professor, Immunology, University of Pittsburgh

Bradlee Heckmann

Bradlee Heckmann

CSO, Asha Therapeutics

Shahram Salek-Ardakani

Shahram Salek-Ardakani

Chief Scientific Officer, Janux Therapeutics

John M. Burke

John M. Burke

President, CEO, and Co-founder  , Applied BioMath

Shailesh Dudhgaonkar

Shailesh Dudhgaonkar

Deputy Research Director , Biocon Bristol Myers Squibb R&D Center (BBRC)

Raed Samara Ph.D

Raed Samara Ph.D

Associate Director, Global Product Management, NGS , QIAGEN

Geert Mudde

Geert Mudde

CSO and Managing Director, Founder, OncoQR ML GmbH, S-TARget therapeutics

Hani Gabra

Hani Gabra

Co-Founder/ Chief Scientific Officer, Papyrus Therapeutics

Sashka Dimitrievska

Sashka Dimitrievska

Senior Director & Therapeutic Area Head for Oncology & Immuno-Oncology Information Practice , AstraZeneca

Eric Halioua

Eric Halioua

President & CEO, PDC*line Pharma

Alem Truneh

Alem Truneh

Co-founder & Chief Technology Officer, ImCheck Therapeutics

Cyril Konto	V

Cyril Konto V

ice-President of Clinical Development , Allogene Therapeutics

SPONSORS